Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Kiora Pharmaceuticals, Inc. Market Cap
The Kiora Pharmaceuticals, Inc. (KPRX) share price is expected to increase by 1012.64% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered KPRX. Price targets range from $27 at the low end to $54 at the high end. The current analyst consensus for KPRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
KPRX is a stock in Healthcare which has been forecasted to be worth $40.5 as an average. On the higher end, the forecast price is $54 USD by from and on the lower end KPRX is forecasted to be $27 by from .
These are the latest 20 analyst ratings of KPRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yi Chen HC Wainwright & Co. | Buy | $10 | Reiterates | Nov 12, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 22, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Maintains | Jul 23, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $2 | Reiterates | May 20, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $2 | Maintains | Mar 27, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $2 | Maintains | Feb 9, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $3.5 | Reiterates | Nov 13, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $3.5 | Maintains | Nov 6, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $2 | Reiterates | Aug 24, 2023 |
HC Wainwright & Co. | Buy | Maintains | Aug 14, 2023 | |
Maxim Group | Buy | Maintains | Aug 9, 2023 | |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Maintains | May 12, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Reiterates | Mar 24, 2023 |
| Michael Okunewitch Maxim Group | Buy | $12 | Upgrade | Feb 9, 2023 |
| Matthew Kaplan Ladenburg Thalmann | Buy | $119 | Reiterates | Feb 8, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $10 | Reiterates | Feb 8, 2023 |
| Matthew Kaplan Ladenburg Thalmann | Buy | $6.5 | Initiates | Aug 25, 2022 |
Maxim Group | Hold | Downgrade | Aug 15, 2022 | |
| Yi Chen HC Wainwright & Co. | Buy | $2.5 | Maintains | Jul 11, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $3 | Maintains | Apr 19, 2022 |
When did it IPO
2015
Staff Count
12
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Brian M. Strem Ph.D.
Market Cap
$10.4M
In 2023, KPRX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KPRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) announced Q3 2024 financial results, including approval for a Phase 2 study of KIO-301 for retinitis pigmentosa, marking progress in its retinal disease pipeline.
Why It Matters - Kiora's Q3 results and Phase 2 study approval for KIO-301 signal potential advancements in retinal disease treatments, influencing future stock performance and market confidence.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) received regulatory approval for a Phase 2 trial of KIO-301 aimed at vision restoration in retinitis pigmentosa patients, involving 36 participants.
Why It Matters - Kiora Pharmaceuticals' Phase 2 trial approval for KIO-301 signals potential advancements in treating retinitis pigmentosa, which could enhance its market value and attract investor interest.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in investor conferences, with live and on-demand presentations available for 90 days on their IR homepage.
Why It Matters - Kiora Pharmaceuticals' participation in investor conferences enhances visibility, potentially attracting new investors and impacting stock price through increased engagement and interest.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2024 results and finalized trial design for Phase 2 study ABACUS-2 of KIO-301, targeting retinitis pigmentosa, in partnership with Théa Open Innovation.
Why It Matters - Kiora Pharmaceuticals' Q2 results and pipeline updates highlight progress in retinal disease treatments, potentially influencing stock performance and investor sentiment on future growth prospects.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Orphan Medicinal Product Designation from the EMA for KIO-301, aimed at treating inherited retinal diseases, including retinitis pigmentosa.
Why It Matters - Kiora Pharmaceuticals' Orphan Medicinal Product Designation in Europe enhances its market potential, reduces regulatory hurdles, and may attract investment, boosting stock performance.
Wed, 10 Jul 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Kiora Pharmaceuticals (NASDAQ: KPRX) announced Dr. Eric Daniels will present at the Jones Trading Healthcare Seaside Summit on July 15 at 6:15 PM ET.
Why It Matters - Kiora Pharmaceuticals' presentation at a key healthcare summit could signal strategic developments or partnerships, impacting stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
